Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 49

Sort by

Sort Order Select

Journal Articles

Risk prediction for clonal cytopenia: multicenter real-world evidence

Blood (2024) 144 (19): 2033–2044.

https://doi.org/10.1182/blood.2024024756

Published: 2024

Includes: Supplemental data

Journal Articles

Patients with a cardiac complete response in AL amyloidosis have survival rates similar to those of a matched general population

Eli Muchtar, Susan Geyer, Giampaolo Merlini, Morie A. Gertz

Blood (2024) 144 (7): 790–793.

https://doi.org/10.1182/blood.2024024623

Published: 2024

Includes: Supplemental data

Journal Articles

TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype

Blood (2020) 136 (24): 2812–2823.

https://doi.org/10.1182/blood.2020006158

Published: 2020

Includes: Supplemental data

Journal Articles

A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403

Blood (2019) 133 (14): 1548–1559.

https://doi.org/10.1182/blood-2018-10-881961

Published: 2019

Includes: Supplemental data

Journal Articles

Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era

Blood (2017) 129 (13): 1763–1767.

https://doi.org/10.1182/blood-2016-10-747170

Published: 2017

Journal Articles

A Prospective, Randomized Study of Cyclosporine or Corticosteroids As an Adjunct to Plasma Exchange for the Treatment of Thrombotic Thrombocytopenic Purpura

Spero Cataland, Shangbin Yang, PhD, Camila Masias Castanon, MD, Michael McGookey, Haiwa Wu, Susan Geyer, PhD, James N. George, MD, Lauren Jay, Haifeng M Wu, MD

Blood (2016) 128 (22): 133.

https://doi.org/10.1182/blood.V128.22.133.133

Published: 2016

Journal Articles

The Multi-Kinase Inhibitor Midostaurin (M) Prolongs Survival Compared with Placebo (P) in Combination with Daunorubicin (D)/Cytarabine (C) Induction (ind), High-Dose C Consolidation (consol), and As Maintenance (maint) Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients (pts) Age 18-60 with FLT3 Mutations (muts): An International Prospective Randomized (rand) P-Controlled Double-Blind Trial (CALGB 10603/RATIFY [Alliance])

Blood (2015) 126 (23): 6.

https://doi.org/10.1182/blood.V126.23.6.6

Published: 2015

Journal Articles

Favorable Outcomes for Older Adolescents and Young Adults (AYA) with Acute Lymphoblastic Leukemia (ALL): Early Results of U.S. Intergroup Trial C10403

Blood (2014) 124 (21): 796.

https://doi.org/10.1182/blood.V124.21.796.796

Published: 2014

Journal Articles

Adding KIT Inhibitor Dasatinib (DAS) to Chemotherapy Overcomes the Negative Impact of KIT Mutation/over-Expression in Core Binding Factor (CBF) Acute Myeloid Leukemia (AML): Results from CALGB 10801 (Alliance)

Guido Marcucci, MD, Susan Geyer, PhD, Weiqiang Zhao, MD PhD, Andrew J Caroll, PhD, Donna Bucci, Geoffrey L. Uy, MD, William Blum, MD, Timothy Pardee, MD PhD, Meir Wetzler, MD, Wendy Stock, MD, Jonathan E. Kolitz, MD, Ann-Kathrin Eisfeld, MD, Clara D. Bloomfield, MD, Richard M. Stone, MD, Richard A. Larson

Blood (2014) 124 (21): 8.

https://doi.org/10.1182/blood.V124.21.8.8

Published: 2014

Journal Articles

Obesity Does Not Affect the Recurrence Free Survival Rates in Children Less Than 20 Years of Age in Acute Promyelocytic Leukemia (APL)

Ji Heon (Paul) Lee, MDPhD, Alfred W. Rademaker, PhD, Bayard L. Powell, MD, Susan Geyer, PhD, Richard A. Larson, John Gregory, MD, Nobuko Hijiya, MD, James H. Feusner, MD

Blood (2014) 124 (21): 957.

https://doi.org/10.1182/blood.V124.21.957.957

Published: 2014

Journal Articles

Phase II Trial Evaluating the Safety and Efficacy of Atorvastatin for the Prophylaxis of Acute Graft Vs. Host Disease (aGVHD) in Patients with Hematological Malignancies Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo HSCT)

Yvonne A Efebera, MD, Susan Geyer, PhD, Anissa Bingman, M.S., Patrick Elder, MS, Rhonda Kitzler, BS, Kevin Coombes, PhD, Carrie Hennelly, MA, Katie Cortright, BS, Leslie A. Andritsos, MD, Samantha M. Jaglowski, MD MPH, Sumithira Vasu, MBBS, William Blum, MD, Rebecca B. Klisovic, MD, Sam Penza, MD, Craig C Hofmeister, MD MPH, Don M Benson, MD PhD, Gerard Lozanski, MD, Steven M. Devine, MD

Blood (2014) 124 (21): 3929.

https://doi.org/10.1182/blood.V124.21.3929.3929

Published: 2014

Journal Articles

Effect of Young Age on Outcomes in Pediatric Acute Promyelocytic Leukemia (APL): North American Intergroup Study CALGB 9710 (Alliance)

Matthew A. Kutny, MD, Susan Geyer, PhD, Kristina M Laumann, BA, John Gregory, MD, Cheryl L. Willman, MD, Wendy Stock, MD, Richard A. Larson, Bayard L. Powell, MD, James H. Feusner, MD

Blood (2014) 124 (21): 2301.

https://doi.org/10.1182/blood.V124.21.2301.2301

Published: 2014

Journal Articles

A Comparison of Outcomes Between Adolescents and Young Adults (AYA) and Children with Acute Promyelocytic Leukemia (APL): North American Intergroup Study CALGB 9710 (Alliance)

Matthew A. Kutny, MD, Susan Geyer, PhD, Kristina M Laumann, BA, John Gregory, MD, Cheryl L. Willman, MD, Wendy Stock, MD, Richard A. Larson, Bayard L. Powell, MD, James H. Feusner, MD

Blood (2014) 124 (21): 2306.

https://doi.org/10.1182/blood.V124.21.2306.2306

Published: 2014

Journal Articles

Impact of Atorvastatin on Cellular Immunome of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT)

Yvonne A Efebera, MD, Susan Geyer, PhD, Anissa Bingman, M.S., Rhonda Kitzler, BS, Patrick Elder, MS, Leslie A. Andritsos, MD, Samantha M. Jaglowski, MD MPH, Sumithira Vasu, MBBS, William Blum, MD, Rebecca B. Klisovic, MD, Sam Penza, MD, Kevin Coombes, PhD, Craig C Hofmeister, MD MPH, Don Benson, MD PhD, Steven M. Devine, MD, Gerard Lozanski, MD

Blood (2014) 124 (21): 1166.

https://doi.org/10.1182/blood.V124.21.1166.1166

Published: 2014

Journal Articles

Dinaciclib (SCH 727965) and Ofatumumab for the Treatment of Relapsed and Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): Results of a Phase 1b/2 Study

Jeffrey Alan Jones, MD MPH, Susan Geyer, PhD, Leslie A. Andritsos, MD, Farrukh Awan, MD MS, Joseph M Flynn, DO, MPH, Kami J. Maddocks, MD, Anissa Bingman, M.S., Amy J. Johnson, PhD, Nyla A. Heerema, PhD, Cathy Brookfield, RN, John C. Byrd, MD, Michael R. Grever, MD

Blood (2014) 124 (21): 329.

https://doi.org/10.1182/blood.V124.21.329.329

Published: 2014

Journal Articles

Allograft T-Cell, T-Regs, NK-Cell and B-Cell Content Influence Distinct Clinical Outcomes Following G-CSF Mobilized Hematopoietic Stem Cell Transplantation

Sumithira Vasu, MBBS, Anissa Bingman, M.S., Susan Geyer, PhD, Patrick Elder, Rhonda Kitzler, BS, Hillary Bradbury, Lynn Odonnell, William Blum, MD, Samantha M. Jaglowski, MD MPH, Leslie A. Andritsos, MD, Rebecca B. Klisovic, MD, Sam Penza, MD, Yvonne A Efebera, MD, Craig C. Hofmeister, MD, Don M. Benson, MD PhD, Natarajan Muthusamy, DVM, PhD, Gerard Lozanski, MD, Steven M. Devine, MD

Blood (2014) 124 (21): 2494.

https://doi.org/10.1182/blood.V124.21.2494.2494

Published: 2014

Journal Articles

Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia

Blood (2014) 124 (1): 42–48.

https://doi.org/10.1182/blood-2014-02-555722

Published: 2014

Includes: Supplemental data

Journal Articles

Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP

Spero R. Cataland, V. Michael Holers, Susan Geyer, Shangbin Yang, Haifeng M. Wu

Blood (2014) 123 (24): 3733–3738.

https://doi.org/10.1182/blood-2013-12-547067

Published: 2014

Includes: Supplemental data

Journal Articles

Implications of the miR-10 family in chemotherapy response of NPM1 -mutated AML

Violaine Havelange, Parvathi Ranganathan, Susan Geyer, Deedra Nicolet, Xiaomeng Huang, Xueyan Yu, Stefano Volinia, Steven M. Kornblau, Michael Andreeff, Carlo M. Croce, Guido Marcucci, Clara D. Bloomfield, Ramiro Garzon

Blood (2014) 123 (15): 2412–2415.

https://doi.org/10.1182/blood-2013-10-532374

Published: 2014

Includes: Supplemental data

Journal Articles

Circulating Mir- 16 and Mir- 25 As New Prognosticators For Multiple Myeloma

Blood (2013) 122 (21): 1853.

https://doi.org/10.1182/blood.V122.21.1853.1853

Published: 2013

NARROW

Risk prediction for clonal cytopenia: multicenter real-world evidence

Patients with a cardiac complete response in AL amyloidosis have survival rates similar to those of a matched general population

TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype

A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403

Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era

A Prospective, Randomized Study of Cyclosporine or Corticosteroids As an Adjunct to Plasma Exchange for the Treatment of Thrombotic Thrombocytopenic Purpura

Favorable Outcomes for Older Adolescents and Young Adults (AYA) with Acute Lymphoblastic Leukemia (ALL): Early Results of U.S. Intergroup Trial C10403

Adding KIT Inhibitor Dasatinib (DAS) to Chemotherapy Overcomes the Negative Impact of KIT Mutation/over-Expression in Core Binding Factor (CBF) Acute Myeloid Leukemia (AML): Results from CALGB 10801 (Alliance)

Obesity Does Not Affect the Recurrence Free Survival Rates in Children Less Than 20 Years of Age in Acute Promyelocytic Leukemia (APL)

Phase II Trial Evaluating the Safety and Efficacy of Atorvastatin for the Prophylaxis of Acute Graft Vs. Host Disease (aGVHD) in Patients with Hematological Malignancies Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo HSCT)

Effect of Young Age on Outcomes in Pediatric Acute Promyelocytic Leukemia (APL): North American Intergroup Study CALGB 9710 (Alliance)

A Comparison of Outcomes Between Adolescents and Young Adults (AYA) and Children with Acute Promyelocytic Leukemia (APL): North American Intergroup Study CALGB 9710 (Alliance)

Impact of Atorvastatin on Cellular Immunome of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT)

Dinaciclib (SCH 727965) and Ofatumumab for the Treatment of Relapsed and Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): Results of a Phase 1b/2 Study

Allograft T-Cell, T-Regs, NK-Cell and B-Cell Content Influence Distinct Clinical Outcomes Following G-CSF Mobilized Hematopoietic Stem Cell Transplantation

Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia

Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP

Implications of the miR-10 family in chemotherapy response of NPM1 -mutated AML

Circulating Mir- 16 and Mir- 25 As New Prognosticators For Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only